Literature DB >> 3987714

Oral BVDU treatment of varicella and zoster in children with cancer.

Y Benoit, G Laureys, M J Delbeke, E De Clercq.   

Abstract

In the period June 1980-April 1983, 21 children with malignant disease were admitted because of an intercurrent varicella or zoster infection. They were treated with the new antiviral drug BVDU [(E)-5-(2-bromovinyl)-2'-deoxyuridine]. The drug was administered orally at a dose of 15 mg/kg per day for 5 days. All our patients responded promptly to BVDU treatment and recovered completely from their varicella or zoster infections without complications. No toxic side-effects due to the drug were observed.

Entities:  

Mesh：

Substances：

Year:  1985        PMID： 3987714     DOI： 10.1007/bf00442138

Source DB:  PubMed          Journal:  Eur J Pediatr        ISSN： 0340-6199            Impact factor:   3.183


  31 in total

1.  Acyclovir in herpes zoster.

Authors:  N A Peterslund; K Seyer-Hansen; J Ipsen; V Esmann; H Schonheyder; H Juhl
Journal:  Lancet       Date:  1981-10-17       Impact factor: 79.321

2.  Intravenous acyclovir therapy for varicella in immunocompromised children.

Authors:  H H Balfour
Journal:  J Pediatr       Date:  1984-01       Impact factor: 4.406

3.  Oral (E)-5-(2-bromovinyl)-2'-deoxyuridine in severe herpes zoster.

Authors:  E de Clercq; H Degreef; J Wildiers; G de Jonge; A Drochmans; J Descamps; P de Somer
Journal:  Br Med J       Date:  1980-11-01

4.  Parenteral acyclovir therapy for herpesvirus infections in man.

Authors:  P J Selby; R L Powles; B Janeson; H E Kay; J G Watson; R Thornton; G Morgenstern; H M Clink; T J McElwain; H G Prentice; R Corringharn; M G Ross; A V Hoffbrand; D Brigden
Journal:  Lancet       Date:  1979-12-15       Impact factor: 79.321

5.  (E)-5-(2-Bromovinyl)-2'-deoxyuridine: a potent and selective anti-herpes agent.

Authors:  E De Clercq; J Descamps; P De Somer; P J Barr; A S Jones; R T Walker
Journal:  Proc Natl Acad Sci U S A       Date:  1979-06       Impact factor: 11.205

6.  Oral (E)-5-(2-bromovinyl)-2'-deoxyuridine treatment of severe herpes zoster in cancer patients.

Authors:  J Wildiers; E De Clercq
Journal:  Eur J Cancer Clin Oncol       Date:  1984-04

7.  Effects of (E)-5-(2-bromovinyl)-2'-deoxyuridine on proliferation of human fibroblasts, peripheral blood mononuclear cells, and granulocyte-monocyte progenitor cells in vitro.

Authors:  A E Wittek; P S Cohen; A M Arvin; S D Smith; C M Koropchak; E De Clercq
Journal:  Antimicrob Agents Chemother       Date:  1983-11       Impact factor: 5.191

8.  Acyclovir treatment of experimental simian varicella infection of monkeys.

Authors:  K F Soike; A D Felsenfeld; P J Gerone
Journal:  Antimicrob Agents Chemother       Date:  1981-09       Impact factor: 5.191

9.  Effect of several antiviral agents on human lymphocyte functions and marrow progenitor cell proliferation.

Authors:  J R Wingard; A D Hess; R K Stuart; R Saral; W H Burns
Journal:  Antimicrob Agents Chemother       Date:  1983-04       Impact factor: 5.191

10.  Comparative efficacy of antiherpes drugs against various strains of varicella-zoster virus.

Authors:  S Shigeta; T Yokota; T Iwabuchi; M Baba; K Konno; M Ogata; E De Clercq
Journal:  J Infect Dis       Date:  1983-03       Impact factor: 5.226
View more
  7 in total

1.  Cell fate control gene therapy based on engineered variants of human deoxycytidine kinase.

Authors:  Anton Neschadim; James C M Wang; Takeya Sato; Daniel H Fowler; Arnon Lavie; Jeffrey A Medin
Journal:  Mol Ther       Date:  2012-01-24       Impact factor: 11.454

2.  Selective in vitro and in vivo activities of 5-(2-haloalkyl)pyrimidine nucleoside analogs, particularly 5-(2-chloroethyl)-2'-deoxyuridine, against herpes simplex virus.

Authors:  E De Clercq; B Rosenwirth
Journal:  Antimicrob Agents Chemother       Date:  1985-08       Impact factor: 5.191

Review 3.  In search of a selective antiviral chemotherapy.

Authors:  E De Clercq
Journal:  Clin Microbiol Rev       Date:  1997-10       Impact factor: 26.132

4.  Comparative activities of several nucleoside analogs against influenza A, B, and C viruses in vitro.

Authors:  S Shigeta; K Konno; T Yokota; K Nakamura; E De Clercq
Journal:  Antimicrob Agents Chemother       Date:  1988-06       Impact factor: 5.191

5.  Antiviral therapy of varicella-zoster virus infection in immunocompromised children--a prospective randomized study of aciclovir versus brivudin.

Authors:  M Heidl; H Scholz; W Dörffel; J Hermann
Journal:  Infection       Date:  1991 Nov-Dec       Impact factor: 3.553

Review 6.  Recognition and treatment of shingles.

Authors:  A F Nikkels; G E Piérard
Journal:  Drugs       Date:  1994-10       Impact factor: 9.546

Review 7.  Current pharmacological approaches to the therapy of varicella zoster virus infections: a guide to treatment.

Authors:  R Snoeck; G Andrei; E De Clercq
Journal:  Drugs       Date:  1999-02       Impact factor: 11.431
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.